The Global Cancer Monoclonal Antibody Partnering Terms and
Agreements 2010-2016: Deal trends, players, financials and forecasts report
provides comprehensive understanding and unprecedented access to the cancer
monoclonal antibody partnering deals and agreements entered into by the worlds
leading healthcare companies
Description
The Global Cancer Monoclonal Antibody Partnering 2010-2016:
Deal trends, players, financials and forecasts report provides an understanding
and access to the cancer monoclonal antibody partnering deals and agreements
entered into by the worlds leading healthcare companies.
- Trends in cancer monoclonal antibody partnering deals
- Most active companies in cancer monoclonal antibody partnering
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Cancer monoclonal antibody partnering contract documents
- Top cancer monoclonal antibody deals by value
This report provides details of the latest Cancer monoclonal
antibody agreements announced in the healthcare sectors.
This report provides details of the latest antibody
agreements announced in the healthcare sectors, covering:
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
Understanding the flexibility of a prospective partner’s
negotiated deals terms provides critical insight into the negotiation process
in terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments clauses,
the devil is in the detail in terms of how payments are triggered – contract
documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all Cancer
monoclonal antibody partnering deals announced since Jan 2010, including
financial terms where available, including links to online deal records of
actual Cancer monoclonal antibody partnering deals as disclosed by the deal
parties. In addition, where available, records include contract documents as submitted
to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation
of Cancer monoclonal antibody dealmaking and business activities. Chapter 1
provides an introduction to the report, whilst chapter 2 provides an overview
of the trends in Cancer monoclonal antibody dealmaking since 2010, including
details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Cancer monoclonal
antibody deals since 2010. Deals are listed by headline value, signed by big
pharma, most active Cancer monoclonal antibody dealmaking companies. Where the
deal has an agreement contract published at the SEC a link provides online
access to the contract.
Chapter 4 provides a comprehensive listing of the top 25
most active companies in Cancer monoclonal antibody dealmaking with a brief
summary followed by a comprehensive listing of Cancer monoclonal antibody
deals, as well as contract documents available in the public domain. Where
available, each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of
Cancer monoclonal antibody partnering deals signed and announced since Jan
2010, where a contract document is available in the public domain. The chapter
is organized by company A-Z, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink
to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of
Cancer monoclonal antibody partnering deals signed and announced since Jan
2010. The chapter is organized by specific Cancer monoclonal antibody
technology type in focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized
by Cancer monoclonal antibody partnering company A-Z, deal type definitions and
Cancer monoclonal antibody partnering agreements example. Each deal title links
via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that
illustrate the trends and activities in Cancer monoclonal antibody partnering
and dealmaking since 2010.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and
commercialization of Cancer monoclonal antibody technologies and products.
Key benefits
Global Cancer Monoclonal Antibody Partnering Terms &
Agreements provides the reader with the following key benefits:
- In-depth understanding of cancer monoclonal antibody deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
- Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
- Identify most active companies in cancer monoclonal antibody partnering
- Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- Spot the emerging companies in the cancer monoclonal antibody area
Report scope
Global Cancer Monoclonal Antibody Partnering Terms &
Agreements is intended to provide the reader with an in-depth understanding and
access to cancer monoclonal antibody trends and structure of deals entered into
by leading companies worldwide.
Cancer Monoclonal Antibody Partnering Terms & Agreements
includes:
- Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2010
- Analysis of cancer monoclonal antibody deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 360 cancer monoclonal antibody deal records
- The leading cancer monoclonal antibody deals by value since 2010
In Cancer Monoclonal Antibody Partnering Terms &
Agreements, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology therapy target
- Monoclonal antibody type
The Cancer Monoclonal Antibody Partnering Terms &
Agreements report provides comprehensive access to available deals and contract
documents for over 360 cancer monoclonal antibody deals. Analyzing actual
contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal
trends, players, financials and forecasts provides the reader with the
following key benefits:
- In-depth understanding of cancer monoclonal antibody deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
- Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
- Identify the most active companies engaged in cancer monoclonal antibody partnering
- Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 303 pages “Global Cancer
Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends,
players and financials” report covers Executive Summary, Introduction, Trends in
Cancer monoclonal antibody dealmaking, Leading Cancer monoclonal antibody
deals, Most active Cancer monoclonal antibody dealmakers, Cancer monoclonal
antibody contracts dealmaking directory, Cancer monoclonal antibody dealmaking
by technology type, Partnering resource center, Appendices.
For
more information Visit at: http://mrr.cm/3Jr
Related Reports;
Global Bioinformatics Partnering Terms and Agreements 2010
to 2016 - Visit at - http://mrr.cm/3JH
Global Molecular Diagnostics 2010-2016: Deal trends,
players, financials and forecasts - Visit at - http://mrr.cm/3JV
Global Diagnostic Imaging Partnering Terms and Agreements
2010 to 2016 - Visit at - http://mrr.cm/3Jj
Global Oncology Partnering 2010-2016: Deal trends, players
and financials - Visit at - http://mrr.cm/3J9
No comments:
Post a Comment
Note: only a member of this blog may post a comment.